EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues

Tao Liu, Lubing Gu, Anna Mui, Zhongzhi Wu, Najah Albadari, Wei Li, Muxiang Zhou

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Tao Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, 30322, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Apoptosis, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, Emory University School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The MDM2 oncogene is amplified and/or overexpressed in various human cancers and elevated expression of MDM2 protein acts as a survival factor promoting cancer progression through both p53-dependent and -independent pathways. Here, we report a novel small-molecule chemical compound (MX69-102) that we identified to induce MDM2 protein degradation, resulting in reactivation of p53, inhibition of XIAP, and potent cell growth inhibition and apoptosis in MDM2-overexpressing acute lymphoblastic leukemia (ALL) in vitro and in vivo. We have previously identified a compound (MX69) that binds to the MDM2 C-terminal RING domain and induces MDM2 protein degradation. In the present study, we performed structural modifications of MX69 and selected analog MX69-102, showing increased MDM2-targeting activity. MX69-102 exhibited significantly enhanced inhibitory and apoptotic effects on a group of MDM2-overexpressing ALL cell lines in vitro with IC50 values of about 0.2 μM, representing an approximately 38-fold increase in activity compared to MX69. MX69-102 also showed effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. Importantly, MX69-102 had minimal or no inhibitory effect on normal human hematopoiesis in vitro and was very well tolerated in vivo in animal models. Based on the strong inhibitory and apoptotic activity against MDM2-overexpressing ALL, along with minimal or no toxicity to normal cells/tissues, MX69-102 is a candidate for further development as a novel MDM2-targeted therapeutic drug for refractory/MDM2-overexpressing ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2Precursor Cell Lymphoblastic Leukemia-LymphomaApoptosisXenograft Model Antitumor AssaysMice, SCIDTumor Suppressor Protein p53HumansAnimalsCell Line, TumorAntineoplastic AgentsCell ProliferationProteolysisX-Linked Inhibitor of Apoptosis ProteinDose-Response Relationship, DrugMiceFemaleStructure-Activity Relationship

Stichwörter der Autor:innen

Acute lymphoblastic leukemiaMDM2 degradationSmall-molecule inhibitor

Substanzen

Proto-Oncogene Proteins c-mdm2MDM2 protein, humanTumor Suppressor Protein p53Antineoplastic AgentsX-Linked Inhibitor of Apoptosis ProteinXIAP protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Department of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, 30322, USA.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. Electronic address: wli@uthsc.edu.
  • Department of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, 30322, USA. Electronic address: mzhou@emory.edu.

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • Emory University School of Medicine
  • Andrew McDonough B+ Foundation
  • Alex's Lemonade Stand Foundation for Childhood Cancer
  • University of Tennessee Health Science Center

Zitieren

APA

Liu, T., Gu, L., Mui, A., Wu, Z., Albadari, N., Li, W., & Zhou, M. (2024). An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217126

Vancouver

Liu T, Gu L, Mui A, Wu Z, Albadari N, Li W, et al. An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217126

BibTeX
@article{Liu2024,
  author = {Liu, Tao and Gu, Lubing and Mui, Anna and Wu, Zhongzhi and Albadari, Najah and Li, Wei and Zhou, Muxiang},
  title = {An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217126}
}
Kostenlos starten →